Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

Completed · Not applicable · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.

Key facts

Study ID

NCT01667926

Run by

Massachusetts General Hospital

People needed

37

Starts

2013-01-01

Expected to finish

2015-11-01

Last updated by the study team

2017-04-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatient with sever treatment resistant depression
• Currently depressed
• Currently under regular psychiatric care
• On an aggressive antidepressant regimen, stable for 4 weeks.

You may not qualify if…

• No history of other major psychiatric illness, including bipolar
• No history of psychosis
• No history of drug abuse
• No major medical illness or unstable medical problem

Where it is running

• Depression Clinical and Reseach Program - MGH — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.